Tesamorelin Research Guide
Tesamorelin Research Guide
Tesamorelin is a full-length GHRH(1-44) analogue with one of the most extensively documented clinical research histories of any synthetic GHRH peptide. It is studied for GH-axis signalling, IGF-1 response, visceral adipose tissue, and metabolic pathway research.
Quick Research Reference
REF- Peptide Class
- GHRH analogue (full-length)
- Structure
- Modified GHRH(1-44)
- Also Known As
- Tesa, TH9507
- Common Research Range
- 1–2 mg daily
- Study Frequency
- Once daily
- Reconstitution
- Bacteriostatic water
- Storage After Reconstitution
- 2–8°C
- Product Size
- 10mg vial
- Research Use Status
- Lab use only
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH) built on the complete 44-amino-acid GHRH sequence, with a trans-3-hexenoic acid modification at the N-terminus that improves peptide stability while preserving GHRH receptor binding activity.
Unlike shorter GHRH fragments such as Sermorelin, which is based on GHRH(1-29), tesamorelin uses the full-length human GHRH(1-44) sequence. This structural completeness, combined with its N-terminal modification, gives tesamorelin an unusually robust clinical documentation record relative to other synthetic GHRH analogues.
Tesamorelin is the active ingredient in Egrifta, an FDA-approved prescription medicine used in the management of HIV-associated lipodystrophy. As a research reference compound, this regulatory and clinical history makes tesamorelin one of the most thoroughly studied GHRH peptides available.
Peptide House supplies Tesamorelin 10mg for laboratory and research use only.
Why Tesamorelin Stands Apart in Research
Most synthetic peptides studied for GH-axis activity have limited published human data. Tesamorelin is an exception. Its path through Phase 2 and Phase 3 clinical trials before FDA approval gives researchers access to a depth of pharmacokinetic, pharmacodynamic, and outcomes data that is rare among GHRH analogues.
Documented Research Depth
Tesamorelin is backed by a body of published evidence that makes it a key reference compound for GH-axis research. Key documentation available in the literature includes:
- Phase 2 and Phase 3 randomised controlled trial data
- Published pharmacokinetic and pharmacodynamic profiles
- Documented GH and IGF-1 response patterns in human subjects
- CT-based visceral adipose tissue measurement data
- Long-term follow-up data from extension studies
- Known receptor binding characteristics at GHRH receptor
- Established once-daily protocol reference in published human studies
This clinical history distinguishes tesamorelin from most other GHRH analogues used in research, where published human data is limited or absent.
How Tesamorelin Is Thought to Work
Tesamorelin acts as a synthetic GHRH receptor agonist. Its mechanism follows the endogenous GHRH signalling pathway, stimulating pituitary somatotroph cells to release growth hormone in a pulsatile pattern consistent with physiological GH release.
GHRH Receptor Binding
Tesamorelin binds to growth hormone-releasing hormone receptors located on pituitary somatotroph cells. The N-terminal trans-3-hexenoic acid modification improves stability without disrupting receptor binding.
Pituitary Stimulation and GH Release
Receptor activation triggers intracellular signalling cascades, including cAMP elevation, that stimulate the synthesis and pulsatile release of endogenous growth hormone from somatotroph cells.
Downstream IGF-1 Production
Released growth hormone travels to the liver and peripheral tissues, where it stimulates the production of IGF-1. Elevated IGF-1 is one of the primary biomarkers tracked in tesamorelin research.
GH/IGF-1 Axis Downstream Effects
The GH/IGF-1 axis then influences metabolic signalling, lipolysis, adipose tissue distribution, protein synthesis, and body composition — all areas examined in published tesamorelin clinical research.
Pulsatile Release Preservation
Because tesamorelin stimulates the body’s own GH release pathway rather than delivering exogenous GH directly, it preserves the pulsatile pattern of GH secretion. This is a key distinction between GHRH analogues and direct GH administration in research models.
Research Applications
Tesamorelin is studied across several interconnected areas of growth hormone, metabolic, and body composition research. Its clinical documentation makes it particularly valuable as a reference compound in these fields.
GH-Axis and Pituitary Research
The primary research application for tesamorelin is studying GHRH receptor activation and the downstream effects on the somatotropic axis. Its documented pharmacokinetics make it a reliable reference compound for pituitary signalling research.
Research areas include:
- GHRH receptor activation and pituitary signalling
- Pulsatile growth hormone release patterns
- IGF-1 response quantification
- Dose-response relationships in GH secretagogue research
- Somatotropic axis function and modulation
- Comparison with other GHRH analogues in GH-axis models
Tesamorelin’s published human pharmacokinetic data makes it valuable as a benchmark when designing GH-axis research protocols.
Visceral Adipose Tissue and Body Composition Research
Tesamorelin’s FDA approval history is directly tied to its demonstrated effects on visceral adipose tissue in published clinical trials. This makes it a key reference compound in body composition research, particularly studies focused on abdominal and trunk fat distribution.
Research areas include:
- Visceral adipose tissue reduction in controlled research models
- Trunk and abdominal fat assessment methods, including CT-based measurement
- GH-mediated lipolysis and adipose tissue metabolism
- Body composition changes over extended research periods
- Adipose tissue distribution and metabolic correlates
- Comparison of body composition outcomes across GHRH analogues
CT-based visceral fat assessment protocols established in tesamorelin clinical trials are commonly referenced when designing body composition research models.
Metabolic and Lipid Research
Through its effects on the GH/IGF-1 axis, tesamorelin is also studied in relation to broader metabolic signalling. Growth hormone plays a central role in lipid metabolism, substrate utilisation, and energy homeostasis.
Research areas include:
- IGF-1 signalling and downstream metabolic effects
- Lipid metabolism and lipolysis-related pathways
- GH-mediated effects on triglyceride and fatty acid metabolism
- Adipose tissue distribution and metabolic risk markers
- Metabolic response patterns in GH secretagogue models
- Glucose-related monitoring as referenced in clinical literature
Glucose monitoring is discussed in published tesamorelin clinical literature because of the known relationship between GH elevation and insulin sensitivity. Researchers should account for this in metabolic study designs.
Ageing and GH-Axis Decline Research
Age-related decline in GH secretion is a well-documented phenomenon. Tesamorelin is studied in research models examining this decline and the potential for GHRH receptor agonists to support GH-axis signalling in older research populations.
Research areas include:
- GH secretion changes associated with ageing
- GHRH receptor sensitivity across different age groups in research models
- IGF-1 levels and somatotropic axis function over time
- Body composition changes in ageing research models
- Metabolic and body composition correlates of GH-axis decline
This area is studied because somatopause — age-related GH decline — is associated with body composition shifts and metabolic changes that parallel findings in published tesamorelin literature.
Tesamorelin vs Other GHRH Peptides
Tesamorelin is one of several GHRH-related peptides studied for GH-axis research. Understanding the structural and research differences between these compounds is important for study design.
| Peptide | Structure | Half-Life | Key Research Notes |
|---|---|---|---|
| Tesamorelin | Modified GHRH(1-44) with trans-3-hexenoic acid | ~26 minutes | Full-length GHRH analogue; FDA-approved drug history; deepest clinical dataset of any synthetic GHRH peptide |
| Sermorelin | GHRH(1-29) | ~10–20 minutes | Shorter GHRH fragment; historical clinical use; shorter activity window than tesamorelin |
| CJC-1295 No DAC | Modified GHRH(1-29) | ~30 minutes | Improved stability vs native GHRH(1-29); often combined with Ipamorelin in dual-pathway research |
| CJC-1295 DAC | Modified GHRH analogue with DAC attachment | ~6–8 days | Extended half-life; studied for sustained GH elevation rather than pulsatile release models |
Tesamorelin’s key point of difference is its full-length GHRH(1-44) structure and its uniquely extensive published clinical research background, including Phase 3 trial data and FDA regulatory documentation.
Technical Specifications
| Specification | Details |
|---|---|
| Product Name | Tesamorelin |
| Systematic Name | Tesamorelin acetate |
| Other Names | Tesa, TH9507, Egrifta-related active ingredient |
| Peptide Class | GHRH analogue (full-length) |
| Amino Acid Count | 44 |
| N-Terminal Modification | trans-3-hexenoic acid |
| Molecular Formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Molecular Weight | Approximately 5135 Da |
| CAS Number | 218949-48-5 |
| Receptor Target | GHRH receptor (pituitary somatotroph cells) |
| Appearance | White to off-white lyophilised powder |
| Solubility | Soluble in water and aqueous buffers |
| Storage, Lyophilised | 2–8°C short term; -20°C long term |
| Storage, Reconstituted | 2–8°C; handle with sterile technique |
| Product Size | 10mg vial |
| Intended Use | Laboratory research use only |
Reconstitution Information
Tesamorelin is supplied as a lyophilised powder and is commonly reconstituted in laboratory settings using bacteriostatic water or another suitable sterile research solvent.
General Laboratory Handling Considerations
Common reconstitution handling steps in laboratory settings include:
- Allowing the vial and bacteriostatic water to reach room temperature before handling
- Adding solvent slowly down the inside wall of the vial rather than directly onto the powder
- Not shaking the vial — allowing the powder to dissolve naturally or with gentle swirling
- Using sterile equipment and aseptic technique throughout all handling steps
- Refrigerating the solution immediately after reconstitution
- Discarding the solution if it becomes cloudy, discoloured, or contains visible particulate matter
Example Concentration Reference
| Vial Size | Water Added | Concentration | 1mg Reference Volume | 2mg Reference Volume |
|---|---|---|---|---|
| 5mg | 2mL | 2.5mg/mL | 0.4mL | 0.8mL |
| 10mg | 2mL | 5mg/mL | 0.2mL | 0.4mL |
| 10mg | 4mL | 2.5mg/mL | 0.4mL | 0.8mL |
For accuracy, use a peptide reconstitution calculator and ensure all measurements match the intended laboratory protocol. Final concentration depends on vial size and total solvent volume used.
Storage Guidelines
Proper storage is important for maintaining tesamorelin stability and ensuring research consistency across preparations.
Lyophilised Powder
Before reconstitution, tesamorelin should be stored in a sealed vial, protected from heat, light, and moisture.
- Short-term: refrigerated at 2–8°C
- Long-term: frozen at approximately -20°C
- Keep sealed until ready for reconstitution
- Protect from direct light and humidity
- Avoid repeated temperature changes before opening
Reconstituted Solution
After reconstitution, tesamorelin should be refrigerated and handled with sterile technique at all times.
- Refrigerate at 2–8°C when not in active use
- Do not freeze after reconstitution
- Use sterile technique each time the vial is accessed
- Avoid repeated warming and cooling of the solution
- Discard if cloudy, discoloured, or if particles are visible
- Use within the stability window specified by laboratory protocol
Frequently Asked Questions
How does tesamorelin differ from directly administering growth hormone?
Tesamorelin stimulates the pituitary gland to release the body’s own endogenous growth hormone through GHRH receptor activation. Direct GH administration bypasses the pituitary entirely and delivers exogenous growth hormone. Because tesamorelin works upstream via the GHRH pathway, it preserves the pulsatile pattern of GH secretion, which is a key research distinction between GHRH analogues and direct GH administration models.
What does the N-terminal modification in tesamorelin do?
The trans-3-hexenoic acid modification at the N-terminus of tesamorelin improves peptide stability by reducing susceptibility to enzymatic degradation, particularly by dipeptidyl peptidase IV (DPP-IV), while preserving the peptide’s ability to bind and activate the GHRH receptor. This modification is one reason tesamorelin has a more useful pharmacokinetic profile than native GHRH(1-44) in research settings.
What is tesamorelin’s relationship to the drug Egrifta?
Tesamorelin is the active ingredient in Egrifta, an FDA-approved prescription medicine for HIV-associated lipodystrophy. Peptide House Tesamorelin is supplied as a research peptide only. It is not a medicine, is not manufactured to pharmaceutical standards, and is not intended for human or therapeutic use. Its FDA approval history makes it a well-documented reference compound for GHRH research.
Why is visceral adipose tissue a focus of tesamorelin research?
Tesamorelin’s Phase 3 clinical trials specifically measured changes in visceral adipose tissue using CT-based assessment. Growth hormone exerts direct effects on adipose tissue metabolism and lipolysis, and the GH/IGF-1 axis is known to influence adipose tissue distribution. Because tesamorelin stimulates endogenous GH, visceral fat changes became a primary research and clinical endpoint in its published literature.
Why is tesamorelin described as a full-length GHRH analogue?
Most synthetic GHRH peptides used in research are based on truncated fragments of the 44-amino-acid GHRH sequence. Sermorelin, for example, uses GHRH(1-29). Tesamorelin uses the complete 44-amino-acid human GHRH sequence with a stabilising N-terminal modification, making it structurally closer to endogenous GHRH than shorter fragment analogues.
What is IGF-1 and how does it relate to tesamorelin research?
IGF-1 (Insulin-Like Growth Factor 1) is produced primarily in the liver in response to growth hormone stimulation. In tesamorelin research and clinical trials, IGF-1 is used as a key downstream biomarker for GHRH receptor activation — an indirect but reliable measure of whether the GH-axis has been activated. Elevated IGF-1 is one of the primary outcomes tracked in published tesamorelin studies.
Can tesamorelin be studied alongside GHS-R1a agonists like Ipamorelin?
Tesamorelin can be referenced in combination research models alongside ghrelin receptor agonists. Because tesamorelin activates the GHRH pathway and compounds like Ipamorelin activate the separate GHS-R1a pathway, combination models allow researchers to study dual-pathway GH stimulation. Any combination research design should be planned by qualified researchers with appropriate ethical oversight.
What quality documentation should researchers look for with tesamorelin?
Given tesamorelin’s 44-amino-acid sequence complexity, quality verification is especially important. Researchers should look for HPLC purity data confirming the full sequence, mass spectrometry confirmation of molecular weight (approximately 5135 Da), batch-specific certificates of analysis, and clear documentation of the N-terminal trans-3-hexenoic acid modification. Incomplete synthesis or sequence truncation are known quality risks with longer peptides.
Is tesamorelin approved for therapeutic use in Australia?
No. Tesamorelin is not approved by the Therapeutic Goods Administration (TGA) for therapeutic use in Australia. While tesamorelin is the active ingredient in Egrifta, which holds FDA approval in the United States, Peptide House supplies tesamorelin strictly for laboratory and research use only. It is not a medicine and is not intended for human or animal use in any context.
Peptide House Quality Standard
At Peptide House, quality, transparency, and consistency are central to our research peptide range. Tesamorelin is a larger and structurally more complex peptide than most compounds in the research market, which makes quality verification especially important.
Longer peptides carry a higher risk of truncated sequences, incomplete synthesis, and sequence-related impurities. Researchers relying on tesamorelin as a clinical reference compound need confidence that the peptide identity and purity are accurately documented.
Quality concerns specific to larger research peptides like tesamorelin may include:
- Truncated sequences resulting from incomplete synthesis
- Lower-than-stated purity due to sequence complexity
- Incorrect or missing N-terminal modification
- Degraded or oxidised peptide material from poor handling
- Inaccurate peptide content or vial fill weight
- Certificates of analysis lacking mass spectrometry confirmation
Peptide House aims to provide researchers with clear product documentation, careful storage practices, and research peptides supplied with appropriate quality verification.
What Researchers Should Look For
When assessing tesamorelin or any long-sequence research peptide, key quality indicators include:
- HPLC purity data confirming the complete 44-amino-acid sequence
- Mass spectrometry confirmation of molecular weight (~5135 Da)
- Verification of the trans-3-hexenoic acid N-terminal modification
- Batch-specific certificates of analysis
- Clear storage and handling guidance
- Transparent product labelling and supply chain documentation
- Reputable sourcing with appropriate quality control processes
Shop Tesamorelin at Peptide House
Peptide House supplies Tesamorelin 10mg for laboratory and research use only.
| Product | Size | Price |
|---|---|---|
| Tesamorelin | 10mg vial | [Insert price] |
View product details, storage information, and available documentation on the Peptide House product page.
References
Key studies and publications commonly cited in tesamorelin research include:
- Falutz J, et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” New England Journal of Medicine, 2007.
- Falutz J, et al. “Effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled Phase 3 trials with 52 weeks of treatment and 26 weeks of follow-up.” Journal of Acquired Immune Deficiency Syndromes, 2010.
- Grunfeld C, et al. “Long-term placebo-controlled study of the efficacy and safety of tesamorelin in HIV-infected patients with abdominal fat accumulation.” AIDS, 2010.
- Dhillon S. “Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.” Drugs, 2011.
- Clemmons DR, et al. “Tesamorelin treatment in patients with HIV-infected lipodystrophy: effect on glucose metabolism.” Journal of Clinical Endocrinology and Metabolism, 2011.
- Stanley TL, et al. “Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.” Lancet HIV, 2019.
- Falutz J, et al. “A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.” AIDS, 2005.
- Jetté L, et al. “Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats.” Endocrinology, 2005.
- Veldhuis JD, Bowers CY. “Human GH pulsatility: an ensemble property regulated by age and gender.” Journal of Endocrinological Investigation, 2003.
- Sigalos JT, Pastuszak AW. “The safety and efficacy of growth hormone secretagogues.” Sexual Medicine Reviews, 2018.